{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T19:59:44Z","timestamp":1782763184263,"version":"3.54.5"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004192","name":"National Science and Technology Development Agency","doi-asserted-by":"crossref","award":["Research Chair Grant"],"award-info":[{"award-number":["Research Chair Grant"]}],"id":[{"id":"10.13039\/501100004192","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004396","name":"Thailand Research Fund","doi-asserted-by":"crossref","award":["RTA6080003"],"award-info":[{"award-number":["RTA6080003"]}],"id":[{"id":"10.13039\/501100004396","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002842","name":"Chiang Mai University","doi-asserted-by":"crossref","award":["Center of Excellence Award"],"award-info":[{"award-number":["Center of Excellence Award"]}],"id":[{"id":"10.13039\/501100002842","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s00018-019-03340-w","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T16:28:14Z","timestamp":1572020894000},"page":"1571-1589","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Mechanisms and potential interventions associated with the cardiotoxicity of ErbB2-targeted drugs: Insights from in vitro, in vivo, and clinical studies in breast cancer patients"],"prefix":"10.1007","volume":"77","author":[{"given":"Krit","family":"Leemasawat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arintaya","family":"Phrommintikul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siriporn C.","family":"Chattipakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3026-718X","authenticated-orcid":false,"given":"Nipon","family":"Chattipakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,24]]},"reference":[{"key":"3340_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424","journal-title":"CA Cancer J Clin"},{"key":"3340_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235:177\u2013182","journal-title":"Science"},{"key":"3340_CR3","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659\u20131672","journal-title":"N Engl J Med"},{"key":"3340_CR4","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783\u2013792","journal-title":"N Engl J Med"},{"key":"3340_CR5","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1200\/JCO.2006.09.1611","volume":"25","author":"TM Suter","year":"2007","unstructured":"Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn JG, Ageev FT, Hitre E, Groetz J, Iwata H, Knap M, Gnant M, Muehlbauer S, Spence A, Gelber RD, Piccart-Gebhart MJ (2007) Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 25:3859\u20133865","journal-title":"J Clin Oncol"},{"key":"3340_CR6","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10549-014-3253-7","volume":"149","author":"AF Yu","year":"2015","unstructured":"Yu AF, Yadav NU, Lung BY, Eaton AA, Thaler HT, Hudis CA, Dang CT, Steingart RM (2015) Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer. Breast Cancer Res Treat 149:489\u2013495","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 7","key":"3340_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/annonc\/mds293","volume":"23","author":"G Curigliano","year":"2012","unstructured":"Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch A, Cipolla C, Roila F (2012) Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 23(Suppl 7):155\u2013166","journal-title":"Ann Oncol"},{"key":"3340_CR8","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM (2016) 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37:2768\u20132801","journal-title":"Eur Heart J"},{"key":"3340_CR9","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1056\/NEJMcibr1203156","volume":"367","author":"GM Cote","year":"2012","unstructured":"Cote GM, Sawyer DB, Chabner BA (2012) ERBB2 inhibition and heart failure. N Engl J Med 367:2150\u20132153","journal-title":"N Engl J Med"},{"key":"3340_CR10","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.tcb.2006.10.008","volume":"16","author":"B Linggi","year":"2006","unstructured":"Linggi B, Carpenter G (2006) ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol 16:649\u2013656","journal-title":"Trends Cell Biol"},{"key":"3340_CR11","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nature04177","volume":"439","author":"RB Jones","year":"2006","unstructured":"Jones RB, Gordus A, Krall JA, MacBeath G (2006) A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 439:168\u2013174","journal-title":"Nature"},{"key":"3340_CR12","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.18632\/oncotarget.2713","volume":"6","author":"S Hu","year":"2015","unstructured":"Hu S, Sun Y, Meng Y, Wang X, Yang W, Fu W, Guo H, Qian W, Hou S, Li B, Rao Z, Lou Z, Guo Y (2015) Molecular architecture of the ErbB2 extracellular domain homodimer. Oncotarget 6:1695\u20131706","journal-title":"Oncotarget"},{"key":"3340_CR13","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1161\/CIRCULATIONAHA.107.690487","volume":"116","author":"K Lemmens","year":"2007","unstructured":"Lemmens K, Doggen K, De Keulenaer GW (2007) Role of neuregulin-1\/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure. Circulation 116:954\u2013960","journal-title":"Circulation"},{"key":"3340_CR14","doi-asserted-by":"publisher","first-page":"8880","DOI":"10.1073\/pnas.122249299","volume":"99","author":"C Ozcelik","year":"2002","unstructured":"Ozcelik C, Erdmann B, Pilz B, Wettschureck N, Britsch S, Hubner N, Chien KR, Birchmeier C, Garratt AN (2002) Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci USA 99:8880\u20138885","journal-title":"Proc Natl Acad Sci USA"},{"key":"3340_CR15","doi-asserted-by":"publisher","first-page":"H1153","DOI":"10.1152\/ajpheart.00048.2005","volume":"289","author":"H Garcia-Rivello","year":"2005","unstructured":"Garcia-Rivello H, Taranda J, Said M, Cabeza-Meckert P, Vila-Petroff M, Scaglione J, Ghio S, Chen J, Lai C, Laguens RP, Lloyd KC, Hertig CM (2005) Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle. Am J Physiol Heart Circ Physiol 289:H1153\u2013H1160","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"3340_CR16","doi-asserted-by":"publisher","first-page":"e40243","DOI":"10.1371\/journal.pone.0040243","volume":"7","author":"M Munk","year":"2012","unstructured":"Munk M, Memon AA, Goetze JP, Nielsen LB, Nexo E, Sorensen BS (2012) Hypoxia changes the expression of the epidermal growth factor (EGF) system in human hearts and cultured cardiomyocytes. PLoS One 7:e40243","journal-title":"PLoS One"},{"key":"3340_CR17","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/jcp.22354","volume":"226","author":"G Camprecios","year":"2011","unstructured":"Camprecios G, Lorita J, Pardina E, Peinado-Onsurbe J, Soley M, Ramirez I (2011) Expression, localization, and regulation of the neuregulin receptor ErbB3 in mouse heart. J Cell Physiol 226:450\u2013455","journal-title":"J Cell Physiol"},{"key":"3340_CR18","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/toxsci\/kfu150","volume":"141","author":"S Eldridge","year":"2014","unstructured":"Eldridge S, Guo L, Mussio J, Furniss M, Hamre J 3rd, Davis M (2014) Examining the protective role of ErbB2 modulation in human-induced pluripotent stem cell-derived cardiomyocytes. Toxicol Sci 141:547\u2013559","journal-title":"Toxicol Sci"},{"key":"3340_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.yexcr.2005.08.017","volume":"311","author":"GM Cote","year":"2005","unstructured":"Cote GM, Miller TA, Lebrasseur NK, Kuramochi Y, Sawyer DB (2005) Neuregulin-1alpha and beta isoform expression in cardiac microvascular endothelial cells and function in cardiac myocytes in vitro. Exp Cell Res 311:135\u2013146","journal-title":"Exp Cell Res"},{"key":"3340_CR20","doi-asserted-by":"publisher","first-page":"19469","DOI":"10.1074\/jbc.M600399200","volume":"281","author":"K Lemmens","year":"2006","unstructured":"Lemmens K, Segers VF, Demolder M, De Keulenaer GW (2006) Role of neuregulin-1\/ErbB2 signaling in endothelium-cardiomyocyte cross-talk. J Biol Chem 281:19469\u201319477","journal-title":"J Biol Chem"},{"key":"3340_CR21","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1161\/01.CIR.0000138109.32748.80","volume":"110","author":"K Okoshi","year":"2004","unstructured":"Okoshi K, Nakayama M, Yan X, Okoshi MP, Schuldt AJ, Marchionni MA, Lorell BH (2004) Neuregulins regulate cardiac parasympathetic activity: muscarinic modulation of beta-adrenergic activity in myocytes from mice with neuregulin-1 gene deletion. Circulation 110:713\u2013717","journal-title":"Circulation"},{"key":"3340_CR22","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1161\/01.CIR.0000013839.41224.1C","volume":"105","author":"DB Sawyer","year":"2002","unstructured":"Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM (2002) Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 105:1551\u20131554","journal-title":"Circulation"},{"key":"3340_CR23","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1161\/01.CIR.0000114521.88547.5E","volume":"109","author":"K Lemmens","year":"2004","unstructured":"Lemmens K, Fransen P, Sys SU, Brutsaert DL, De Keulenaer GW (2004) Neuregulin-1 induces a negative inotropic effect in cardiac muscle: role of nitric oxide synthase. Circulation 109:324\u2013326","journal-title":"Circulation"},{"key":"3340_CR24","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.yjmcc.2006.08.002","volume":"41","author":"F Timolati","year":"2006","unstructured":"Timolati F, Ott D, Pentassuglia L, Giraud MN, Perriard JC, Suter TM, Zuppinger C (2006) Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. J Mol Cell Cardiol 41:845\u2013854","journal-title":"J Mol Cell Cardiol"},{"key":"3340_CR25","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.yjmcc.2004.12.013","volume":"38","author":"S Rohrbach","year":"2005","unstructured":"Rohrbach S, Muller-Werdan U, Werdan K, Koch S, Gellerich NF, Holtz J (2005) Apoptosis-modulating interaction of the neuregulin\/erbB pathway with anthracyclines in regulating Bcl-xS and Bcl-xL in cardiomyocytes. J Mol Cell Cardiol 38:485\u2013493","journal-title":"J Mol Cell Cardiol"},{"key":"3340_CR26","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.toxlet.2018.01.001","volume":"285","author":"YK Kurokawa","year":"2018","unstructured":"Kurokawa YK, Shang MR, Yin RT, George SC (2018) Modeling trastuzumab-related cardiotoxicity in vitro using human stem cell-derived cardiomyocytes. Toxicol Lett 285:74\u201380","journal-title":"Toxicol Lett"},{"key":"3340_CR27","doi-asserted-by":"publisher","first-page":"H1271","DOI":"10.1152\/ajpheart.00517.2014","volume":"309","author":"F Belmonte","year":"2015","unstructured":"Belmonte F, Das S, Sysa-Shah P, Sivakumaran V, Stanley B, Guo X, Paolocci N, Aon MA, Nagane M, Kuppusamy P, Steenbergen C, Gabrielson K (2015) ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity. Am J Physiol Heart Circ Physiol 309:H1271\u2013H1280","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"3340_CR28","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1535-6108(04)00083-2","volume":"5","author":"MC Franklin","year":"2004","unstructured":"Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX (2004) Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5:317\u2013328","journal-title":"Cancer Cell"},{"key":"3340_CR29","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Dieras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783\u20131791","journal-title":"N Engl J Med"},{"key":"3340_CR30","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2004.08.066","volume":"44","author":"LP Grazette","year":"2004","unstructured":"Grazette LP, Boecker W, Matsui T, Semigran M, Force TL, Hajjar RJ, Rosenzweig A (2004) Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol 44:2231\u20132238","journal-title":"J Am Coll Cardiol"},{"key":"3340_CR31","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.7150\/thno.23207","volume":"8","author":"WT Hsu","year":"2018","unstructured":"Hsu WT, Huang CY, Yen CYT, Cheng AL, Hsieh PCH (2018) The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling. Theranostics 8:3176\u20133188","journal-title":"Theranostics"},{"key":"3340_CR32","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10549-012-2103-8","volume":"134","author":"C Fedele","year":"2012","unstructured":"Fedele C, Riccio G, Malara AE, D\u2019Alessio G, De Lorenzo C (2012) Mechanisms of cardiotoxicity associated with ErbB2 inhibitors. Breast Cancer Res Treat 134:595\u2013602","journal-title":"Breast Cancer Res Treat"},{"key":"3340_CR33","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1074\/jbc.M804570200","volume":"284","author":"LI Gordon","year":"2009","unstructured":"Gordon LI, Burke MA, Singh AT, Prachand S, Lieberman ED, Sun L, Naik TJ, Prasad SV, Ardehali H (2009) Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J Biol Chem 284:2080\u20132087","journal-title":"J Biol Chem"},{"key":"3340_CR34","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.yexcr.2007.02.007","volume":"313","author":"L Pentassuglia","year":"2007","unstructured":"Pentassuglia L, Timolati F, Seifriz F, Abudukadier K, Suter TM, Zuppinger C (2007) Inhibition of ErbB2\/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytes. Exp Cell Res 313:1588\u20131601","journal-title":"Exp Cell Res"},{"key":"3340_CR35","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.2147\/OTT.S157294","volume":"11","author":"C De Lorenzo","year":"2018","unstructured":"De Lorenzo C, Paciello R, Riccio G, Rea D, Barbieri A, Coppola C, Maurea N (2018) Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine. Onco Targets Ther 11:2241\u20132250","journal-title":"Onco Targets Ther"},{"key":"3340_CR36","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s10549-013-2707-7","volume":"141","author":"I Seemann","year":"2013","unstructured":"Seemann I, te Poele JA, Song JY, Hoving S, Russell NS, Stewart FA (2013) Radiation- and anthracycline-induced cardiac toxicity and the influence of ErbB2 blocking agents. Breast Cancer Res Treat 141:385\u2013395","journal-title":"Breast Cancer Res Treat"},{"key":"3340_CR37","doi-asserted-by":"publisher","first-page":"e79543","DOI":"10.1371\/journal.pone.0079543","volume":"8","author":"MK ElZarrad","year":"2013","unstructured":"ElZarrad MK, Mukhopadhyay P, Mohan N, Hao E, Dokmanovic M, Hirsch DS, Shen Y, Pacher P, Wu WJ (2013) Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice. PLoS One 8:e79543","journal-title":"PLoS One"},{"key":"3340_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.biopha.2017.06.033","volume":"93","author":"AM Kabel","year":"2017","unstructured":"Kabel AM, Elkhoely AA (2017) Targeting proinflammatory cytokines, oxidative stress, TGF-beta1 and STAT-3 by rosuvastatin and ubiquinone to ameliorate trastuzumab cardiotoxicity. Biomed Pharmacother 93:17\u201326","journal-title":"Biomed Pharmacother"},{"key":"3340_CR39","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3389\/fphys.2018.00038","volume":"9","author":"G Riccio","year":"2018","unstructured":"Riccio G, Antonucci S, Coppola C, D\u2019Avino C, Piscopo G, Fiore D, Maurea C, Russo M, Rea D, Arra C, Condorelli G, Di Lisa F, Tocchetti CG, De Lorenzo C, Maurea N (2018) Ranolazine attenuates trastuzumab-induced heart dysfunction by modulating ros production. Front Physiol 9:38","journal-title":"Front Physiol"},{"key":"3340_CR40","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","volume":"27","author":"JC Plana","year":"2014","unstructured":"Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, DeCara JM, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalhaes A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P (2014) Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 27:911\u2013939","journal-title":"J Am Soc Echocardiogr"},{"key":"3340_CR41","first-page":"1463","volume":"50","author":"M Cornarotti","year":"1996","unstructured":"Cornarotti M, Tinelli S, Willmore E, Zunino F, Fisher LM, Austin CA, Capranico G (1996) Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIalpha (p170) and IIbeta (p180). Mol Pharmacol 50:1463\u20131471","journal-title":"Mol Pharmacol"},{"key":"3340_CR42","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1172\/JCI72931","volume":"124","author":"Y Ichikawa","year":"2014","unstructured":"Ichikawa Y, Ghanefar M, Bayeva M, Wu R, Khechaduri A, Naga Prasad SV, Mutharasan RK, Naik TJ, Ardehali H (2014) Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest 124:617\u2013630","journal-title":"J Clin Invest"},{"key":"3340_CR43","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/cvr\/cvq148","volume":"87","author":"T Horie","year":"2010","unstructured":"Horie T, Ono K, Nishi H, Nagao K, Kinoshita M, Watanabe S, Kuwabara Y, Nakashima Y, Takanabe-Mori R, Nishi E, Hasegawa K, Kita T, Kimura T (2010) Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway. Cardiovasc Res 87:656\u2013664","journal-title":"Cardiovasc Res"},{"key":"3340_CR44","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1158\/0008-5472.CAN-06-3721","volume":"67","author":"K Gabrielson","year":"2007","unstructured":"Gabrielson K, Bedja D, Pin S, Tsao A, Gama L, Yuan B, Muratore N (2007) Heat shock protein 90 and ErbB2 in the cardiac response to doxorubicin injury. Cancer Res 67:1436\u20131441","journal-title":"Cancer Res"},{"key":"3340_CR45","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1600-079X.2010.00818.x","volume":"50","author":"M Ozturk","year":"2011","unstructured":"Ozturk M, Ozler M, Kurt YG, Ozturk B, Uysal B, Ersoz N, Yasar M, Demirbas S, Kurt B, Acikel C, Oztas Y, Arpaci F, Topal T, Ozet A, Ataergin S, Kuzhan O, Oter S, Korkmaz A (2011) Efficacy of melatonin, mercaptoethylguanidine and 1400\u00a0W in doxorubicin- and trastuzumab-induced cardiotoxicity. J Pineal Res 50:89\u201396","journal-title":"J Pineal Res"},{"key":"3340_CR46","first-page":"857","volume":"35","author":"N Kertmen","year":"2015","unstructured":"Kertmen N, Aksoy S, Uner A, Sargon M, Ozkayar O, Keskin O, Babacan T, Sarici F, Sendur MA, Arik Z, Akin S, Altundag K (2015) Which sequence best protects the heart against trastuzumab and anthracycline toxicity? An electron microscopy study in rats. Anticancer Res 35:857\u2013864","journal-title":"Anticancer Res"},{"key":"3340_CR47","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (neosphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:25\u201332","journal-title":"Lancet Oncol"},{"key":"3340_CR48","doi-asserted-by":"publisher","first-page":"7811","DOI":"10.1200\/JCO.2005.02.4091","volume":"23","author":"E Tan-Chiu","year":"2005","unstructured":"Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, Shannon RP, Swain SM, Brown A, Fehrenbacher L, Vogel VG, Seay TE, Rastogi P, Mamounas EP, Wolmark N, Bryant J (2005) Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23:7811\u20137819","journal-title":"J Clin Oncol"},{"key":"3340_CR49","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"L Gianni","year":"2010","unstructured":"Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375:377\u2013384","journal-title":"Lancet"},{"key":"3340_CR50","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273\u20131283","journal-title":"N Engl J Med"},{"key":"3340_CR51","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","volume":"14","author":"SM Swain","year":"2013","unstructured":"Swain SM, Kim SB, Cortes J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14:461\u2013471","journal-title":"Lancet Oncol"},{"key":"3340_CR52","doi-asserted-by":"publisher","first-page":"5538","DOI":"10.1200\/JCO.2009.23.3734","volume":"27","author":"S Johnston","year":"2009","unstructured":"Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O\u2019Rourke L, Oliva C, Stein S, Pegram M (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27:5538\u20135546","journal-title":"J Clin Oncol"},{"key":"3340_CR53","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1200\/JCO.2011.40.5241","volume":"31","author":"Z Guan","year":"2013","unstructured":"Guan Z, Xu B, DeSilvio ML, Shen Z, Arpornwirat W, Tong Z, Lorvidhaya V, Jiang Z, Yang J, Makhson A, Leung WL, Russo MW, Newstat B, Wang L, Chen G, Oliva C, Gomez H (2013) Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J Clin Oncol 31:1947\u20131953","journal-title":"J Clin Oncol"},{"key":"3340_CR54","doi-asserted-by":"publisher","first-page":"5544","DOI":"10.1200\/JCO.2008.16.2578","volume":"26","author":"A Di Leo","year":"2008","unstructured":"Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, Guerrera SF, Koehler M, Oliva C, Stein SH, Williams LS, Dering J, Finn RS, Press MF (2008) Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26:5544\u20135552","journal-title":"J Clin Oncol"},{"key":"3340_CR55","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1200\/JCO.2007.13.5467","volume":"26","author":"EA Perez","year":"2008","unstructured":"Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, Martino S, Gralow JR, Dakhil SR, Ingle JN, Winer EP, Gelmon KA, Gersh BJ, Jaffe AS, Rodeheffer RJ (2008) Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26:1231\u20131238","journal-title":"J Clin Oncol"},{"key":"3340_CR56","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","volume":"24","author":"A Schneeweiss","year":"2013","unstructured":"Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, McNally V, Ross G, Cortes J (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24:2278\u20132284","journal-title":"Ann Oncol"},{"key":"3340_CR57","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","volume":"377","author":"G von Minckwitz","year":"2017","unstructured":"von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J (2017) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 377:122\u2013131","journal-title":"N Engl J Med"},{"key":"3340_CR58","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","volume":"379","author":"J Baselga","year":"2012","unstructured":"Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gomez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horvath Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379:633\u2013640","journal-title":"Lancet"},{"key":"3340_CR59","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1002\/jcp.25432","volume":"231","author":"L Pizzuti","year":"2016","unstructured":"Pizzuti L, Barba M, Giannarelli D, Sergi D, Botti C, Marchetti P, Anza M, Maugeri-Sacca M, Natoli C, Di Filippo S, Catenaro T, Tomao F, Amodio A, Carpano S, Perracchio L, Mottolese M, Di Lauro L, Sanguineti G, Di Benedetto A, Giordano A, Vici P (2016) Neoadjuvant sequential docetaxel followed by high-dose epirubicin in combination with cyclophosphamide administered concurrently with trastuzumab, the DECT trial. J Cell Physiol 231:2541\u20132547","journal-title":"J Cell Physiol"},{"key":"3340_CR60","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00280-015-2922-5","volume":"77","author":"AL Quartino","year":"2016","unstructured":"Quartino AL, Hillenbach C, Li J, Li H, Wada RD, Visich J, Li C, Heinzmann D, Jin JY, Lum BL (2016) Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous \u201cmanual syringe\u201d injection or intravenously in women with HER2-positive early breast cancer. Cancer Chemother Pharmacol 77:77\u201388","journal-title":"Cancer Chemother Pharmacol"},{"key":"3340_CR61","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.ejca.2015.05.028","volume":"51","author":"X Pivot","year":"2015","unstructured":"Pivot X, Suter T, Nabholtz JM, Pierga JY, Espie M, Lortholary A, Khayat D, Pauporte I, Romieu G, Kramar A, Fumoleau P (2015) Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study. Eur J Cancer 51:1660\u20131666","journal-title":"Eur J Cancer"},{"key":"3340_CR62","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1038\/bjc.2016.357","volume":"115","author":"HM Earl","year":"2016","unstructured":"Earl HM, Vallier AL, Dunn J, Loi S, Ogburn E, McAdam K, Hughes-Davies L, Harnett A, Abraham J, Wardley A, Cameron DA, Miles D, Gounaris I, Plummer C, Hiller L (2016) Trastuzumab-associated cardiac events in the Persephone trial. Br J Cancer 115:1462\u20131470","journal-title":"Br J Cancer"},{"key":"3340_CR63","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/annonc\/mdx773","volume":"29","author":"SM Swain","year":"2018","unstructured":"Swain SM, Ewer MS, Viale G, Delaloge S, Ferrero JM, Verrill M, Colomer R, Vieira C, Werner TL, Douthwaite H, Bradley D, Waldron-Lynch M, Kiermaier A, Eng-Wong J, Dang C (2018) Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol 29:646\u2013653","journal-title":"Ann Oncol"},{"key":"3340_CR64","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1634\/theoncologist.2009-0181","volume":"15","author":"D Cameron","year":"2010","unstructured":"Cameron D, Casey M, Oliva C, Newstat B, Imwalle B, Geyer CE (2010) Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 15:924\u2013934","journal-title":"Oncologist"},{"key":"3340_CR65","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.4161\/cc.7.12.6016","volume":"7","author":"SA Shell","year":"2008","unstructured":"Shell SA, Lyass L, Trusk PB, Pry KJ, Wappel RL, Bacus SS (2008) Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells. Cell Cycle 7:1769\u20131775","journal-title":"Cell Cycle"},{"key":"3340_CR66","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","volume":"15","author":"IE Krop","year":"2014","unstructured":"Krop IE, Kim SB, Gonzalez-Martin A, LoRusso PM, Ferrero JM, Smitt M, Yu R, Leung AC, Wildiers H (2014) Trastuzumab emtansine versus treatment of physician\u2019s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 15:689\u2013699","journal-title":"Lancet Oncol"},{"key":"3340_CR67","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1200\/JCO.2016.67.4887","volume":"35","author":"EA Perez","year":"2017","unstructured":"Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot X, Burris H 3rd, Petersen JA, Stanzel S, Strasak A, Patre M, Ellis P (2017) Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III Marianne study. J Clin Oncol 35:141\u2013148","journal-title":"J Clin Oncol"},{"key":"3340_CR68","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10549-019-05191-2","volume":"175","author":"F Lynce","year":"2019","unstructured":"Lynce F, Barac A, Geng X, Dang C, Yu AF, Smith KL, Gallagher C, Pohlmann PR, Nunes R, Herbolsheimer P, Warren R, Srichai MB, Hofmeyer M, Cunningham A, Timothee P, Asch FM, Shajahan-Haq A, Tan MT, Isaacs C, Swain SM (2019) Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEART study. Breast Cancer Res Treat 175:595\u2013603","journal-title":"Breast Cancer Res Treat"},{"key":"3340_CR69","doi-asserted-by":"publisher","first-page":"4963","DOI":"10.1158\/1078-0432.CCR-09-0628","volume":"15","author":"MJ Haykowsky","year":"2009","unstructured":"Haykowsky MJ, Mackey JR, Thompson RB, Jones LW, Paterson DI (2009) Adjuvant trastuzumab induces ventricular remodeling despite aerobic exercise training. Clin Cancer Res 15:4963\u20134967","journal-title":"Clin Cancer Res"},{"key":"3340_CR70","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1161\/CIRCHEARTFAILURE.112.000055","volume":"6","author":"S Seicean","year":"2013","unstructured":"Seicean S, Seicean A, Alan N, Plana JC, Budd GT, Marwick TH (2013) Cardioprotective effect of beta-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ Heart Fail 6:420\u2013426","journal-title":"Circ Heart Fail"},{"key":"3340_CR71","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","volume":"35","author":"E Pituskin","year":"2017","unstructured":"Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, Pagano JJ, Chow K, Thompson RB, Vos LJ, Ghosh S, Oudit GY, Ezekowitz JA, Paterson DI (2017) Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol 35:870\u2013877","journal-title":"J Clin Oncol"},{"key":"3340_CR72","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","volume":"2","author":"AH Boekhout","year":"2016","unstructured":"Boekhout AH, Gietema JA, Kerklaan BM, van Werkhoven ED, Altena R, Honkoop A, Los M, Smit WM, Nieboer P, Smorenburg CH, Mandigers CM, van der Wouw AJ, Kessels L, van der Velden AW, Ottevanger PB, Smilde T, de Boer J, van Veldhuisen DJ, Kema IP, de Vries EG, Schellens JH (2016) Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial. JAMA Oncol 2:1030\u20131037","journal-title":"JAMA Oncol"},{"key":"3340_CR73","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","volume":"73","author":"M Guglin","year":"2019","unstructured":"Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W, Munster PN (2019) Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J Am Coll Cardiol 73:2859\u20132868","journal-title":"J Am Coll Cardiol"},{"key":"3340_CR74","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.3748\/wjg.v9.i6.1307","volume":"9","author":"WG Dong","year":"2003","unstructured":"Dong WG, Mei Q, Yu JP, Xu JM, Xiang L, Xu Y (2003) Effects of melatonin on the expression of iNOS and COX-2 in rat models of colitis. World J Gastroenterol 9:1307\u20131311","journal-title":"World J Gastroenterol"},{"key":"3340_CR75","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3945\/ajcn.112.040741","volume":"97","author":"AD Fotino","year":"2013","unstructured":"Fotino AD, Thompson-Paul AM, Bazzano LA (2013) Effect of coenzyme Q(1)(0) supplementation on heart failure: a meta-analysis. Am J Clin Nutr 97:268\u2013275","journal-title":"Am J Clin Nutr"},{"key":"3340_CR76","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3988\/jcn.2014.10.2.140","volume":"10","author":"GJ Moon","year":"2014","unstructured":"Moon GJ, Kim SJ, Cho YH, Ryoo S, Bang OY (2014) Antioxidant effects of statins in patients with atherosclerotic cerebrovascular disease. J Clin Neurol 10:140\u2013147","journal-title":"J Clin Neurol"},{"key":"3340_CR77","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.phrs.2011.06.018","volume":"64","author":"M Aldakkak","year":"2011","unstructured":"Aldakkak M, Camara AK, Heisner JS, Yang M, Stowe DF (2011) Ranolazine reduces Ca2+ overload and oxidative stress and improves mitochondrial integrity to protect against ischemia reperfusion injury in isolated hearts. Pharmacol Res 64:381\u2013392","journal-title":"Pharmacol Res"},{"key":"3340_CR78","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/ejhf.50","volume":"16","author":"CG Tocchetti","year":"2014","unstructured":"Tocchetti CG, Carpi A, Coppola C, Quintavalle C, Rea D, Campesan M, Arcari A, Piscopo G, Cipresso C, Monti MG, De Lorenzo C, Arra C, Condorelli G, Di Lisa F, Maurea N (2014) Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction. Eur J Heart Fail 16:358\u2013366","journal-title":"Eur J Heart Fail"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-019-03340-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-019-03340-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-019-03340-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T19:07:41Z","timestamp":1650481661000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-019-03340-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,24]]},"references-count":78,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["3340"],"URL":"https:\/\/doi.org\/10.1007\/s00018-019-03340-w","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,24]]},"assertion":[{"value":"30 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}